Accelerated Approval Great For “Me-Too” Products, FDA Says
Executive Summary
CDER’s Bob Temple explains how competitors could actually help speed up a drug approval but also hold a product to a higher standard.
You may also be interested in...
Genetic Diseases Could See Indication Expansions Through Accelerated Approval
Accelerated approvals likely to increase, particularly for cancer, predicts FDA’s Temple.
A User Guide To FDA’s Expedited Programs For Serious Conditions
A handy side-by-side chart shows the criteria, advantages and timelines for the fast-track, breakthrough therapy and priority review designations and the accelerated approval pathway.
Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data
Monoclonal antibody's label includes studies as monotherapy and as add-on in patients previously treated with Avonex. Two-year results are expected in the first half of 2005.